Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

NCT06825559 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Cholestatic Liver Disease

Interventions

DRUG: Saroglitazar Magnesium 1 mg

Sponsor

Zydus Therapeutics Inc.